Overview

Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

Status:
NOT_YET_RECRUITING

Trial end date:
2028-03-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare effects of weekly SQ semaglutide 2.4mg SQ, SQ tirzepatide 10mg, and placebo administered for 24 weeks on GES measured repeatedly at baseline, 16 weeks, 24 weeks, 28 weeks, 4 weeks after stopping the medication, and accommodation and satiation at 24 weeks compared to baseline.

Phase:

PHASE4

Details

Lead Sponsor:

Mayo Clinic

Treatments:

semaglutide
Tirzepatide